Aurobindo Pharma gets EIR from USFDA for manufacturing facility in Andhra Pradesh

17 Nov 2022 Evaluate

Aurobindo Pharma has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Pydibhimavaram in Andhra Pradesh.

The company's Unit XI at Pydibhimavaram is an API non-antibiotic manufacturing facility. It was inspected by the USFDA in February 2019 and issued a warning letter in June 2019. It was inspected further by the USFDA from July 25 to August 2, 2022 and issued a Form 483 with three observations.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1155.20 -13.70 (-1.17%)
02-Feb-2026 10:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.60
Dr. Reddys Lab 1174.00
Cipla 1299.00
Zydus Lifesciences 868.40
Lupin 2089.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×